Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two phase III trials in MASH for survodutide
October 08, 2024 02:35 ET
|
Boehringer Ingelheim
The U.S. FDA Breakthrough Therapy designation is for the treatment of adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and moderate or advanced fibrosis, based on...
Boehringer’s nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER™-IPF study
September 16, 2024 06:05 ET
|
Boehringer Ingelheim
Topline data from FIBRONEER™-IPF show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change from baseline in Forced Vital Capacity [mL] at week 52...
Triple Hair Group reçoit l'approbation de Santé Canada pour commencer les essais cliniques de phase III sur son médicament sur ordonnance Thérapie-07 au Canada
June 28, 2023 07:00 ET
|
Triple Hair Inc.
MONTRÉAL, 28 juin 2023 (GLOBE NEWSWIRE) -- Triple Hair Group Inc. (« Triple Hair » ou la « Société »), un leader mondial dans le développement de traitements novateurs contre l'alopécie, a le...
Triple Hair Group receives Health Canada approval to start Phase III clinical trials on its Therapy-07 prescription drug in Canada
June 28, 2023 07:00 ET
|
Triple Hair Inc.
MONTRÉAL, June 28, 2023 (GLOBE NEWSWIRE) -- Triple Hair Group Inc. (“Triple Hair” or the “Company”), a global leader in the development of innovative treatments for alopecia, is pleased to...
愛科百發在第12屆國際呼吸道合胞病毒（RSV）年會上報告了愛司韋™在RSV感染的住院嬰幼兒中的三期臨床試驗（AIRFLO）積極結果
October 06, 2022 23:39 ET
|
Shanghai Ark Biopharmaceutical Co., Ltd.
中國上海, Oct. 07, 2022 (GLOBE NEWSWIRE) --...
爱科百发在第12届国际呼吸道合胞病毒（RSV）年会上报告了爱司韦™在RSV感染的住院婴幼儿中的三期临床试验（AIRFLO）积极结果
October 06, 2022 23:39 ET
|
Shanghai Ark Biopharmaceutical Co., Ltd.
中国上海, Oct. 07, 2022 (GLOBE NEWSWIRE) --...
Ark Biopharmaceutical Presents Positive Results in Phase 3 AIRFLO Study of Ziresovir in RSV-Infected Hospitalized Infants at 12th International RSV Symposium
October 06, 2022 23:39 ET
|
Shanghai Ark Biopharmaceutical Co., Ltd.
SHANGHAI, China, Oct. 07, 2022 (GLOBE NEWSWIRE) -- Results from Shanghai Ark Biopharmaceutical Co., Ltd. (Ark Biopharmaceutical)’s successful Phase 3 study (AIRFLO) with the respiratory syncytial...
POP Biotechnologies' SNAP Vaccine Platform Enters Large-Scale Phase III Clinical Trials for COVID-19
September 20, 2022 21:31 ET
|
POP Biotechnologies, Inc.
BUFFALO, N.Y., Sept. 20, 2022 (GLOBE NEWSWIRE) -- POP Biotechnologies (POP BIO), a Buffalo, New York-based biopharmaceutical startup, announces the commencement of two Phase 3 clinical studies of...
Canadian Treatments for COVID-19 (CATCO) Trial Receives Approval from Health Canada to Amend Protocol to include LSALT Peptide (Metablok)
February 14, 2022 07:30 ET
|
Arch Biopartners
TORONTO, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch Biopartners”, “Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug...
ArkBio Announces Completion of Patient Enrollment and Dosing in AIRFLO, a Phase III Registration Trial of Ziresovir for Treatment of Respiratory Syncytial Virus Infection
January 25, 2022 05:06 ET
|
Shanghai Ark Biopharmaceutical Co., Ltd.
SHANGHAI, China, Jan. 25, 2022 (GLOBE NEWSWIRE) -- On January 25, 2022, Shanghai Ark Biopharmaceutical Co., Ltd. (ArkBio) announced the completion of patient enrollment and dosing of ziresovir...